October 17 – 19 2017 | Boston, MA

Hyatt Regency Boston

Day 1
Wednesday October 19th, 2016

Day 2
Thursday October 20th, 2016

Day 3
Friday October 21st, 2016

Tuesday October 18th, 2016


We’re busy building the agenda for 2017

Register your interest here for the latest updates on World CDx Boston 2017.


Register Your Interest



Registration & Breakfast

Chairman’s Opening Remarks

Targeted Immunotherapies, Complementary & Companion Diagnostics

Predictive Biomarkers for Pembrolizumab

  • Eric Rubin Vice President & Therapeutic Area Head, Oncology Early Development, Merck


  • Clinical utility of PD-L1 immunohistochemistry in identifying responders to pembrolizumab
  • Beyond PD-L1 immunohistochemistry – potential of RNA- and DNAbased assays to identify responders to pembrolizumab

Decentralized Multiplexed Companion Diagnostics on the NanoString nCounter Analysis System

  • Sean Ferree Vice President, Diagnostic Development, NanoString Technologies


  • The NanoString nCounter Dx Analysis System is a novel technology that digitally counts single nucleic acid molecules using fluorescent single-molecule barcodes
  • Several companion diagnostic tests are in development including a cell-of-origin subtyping test for diffuse large B-cell lymphoma to select patients for targeted therapies and an immune response signature to predict response to anti-PD1 blockade in multiple solid tumor types

Diagnostics for Cancer Immunotherapies: Present and Future Outlook in Healthcare and Precision Medicine


  • Understand the challenge of companion diagnostics approaches for cancer immunotherapies
  • Discussion will be lead around the interplay of molecular information and diagnostics in a precision medicine strategy accompanying development and adoption of immuno-oncology drugs

Immuno-Oncology Targeting Therapies: Developing Diagnostics to Meet Patient Needs


  • Understand the strategy behind developing diagnostics for different patient populations
  • Evidence Based Diagnostic Utility: Evolution of PD-L1 from a complementary to a companion diagnostic
  • The Bristol-Myers Squibb pipeline and diagnostics to address continued unmet needs in ImmunoOncology

Speed Networking & Morning Refreshments

The Art of Oncology: How to Utilize Biomarker Tests for Immuno-Oncology Treatments in the Real-World

  • Zhen Su Vice President & Head, Global Medical Affairs, Oncology, EMD Serono


  • Understand the strategic and practical implications of how to select the right test at the right time for the right patient
  • Discussion will be led around what is the next wave of biomarkers for immuno-oncology therapies

Fast to Pivotal: An Approach to Cut-Off Determination to go Directly to Pivotal Trial

  • Jay Foust CDx Partnering, Roche Tissue Diagnostics (Ventana)


  • Understand how clinical trial design should have a strategic impact on targeted therapy development
  • Case studies of opportunities where this strategic impact is experienced when developing companion diagnostics

How to Maximise the Value of Biomarkers in Immuno-Oncology: A Role for Companion and Complementary Diagnostics


  • Appreciate the key role that biomarker of immune function will play in the development of next generation immunotherapies
  • Gain an overview of the various biomarkers that are being evaluated in immuno-oncology
  • Define and better understand the value provided by companion and complementary diagnostics for immuno-oncology therapies
  • Learn the key steps to be considered for the successful development and commercialization of a companion or complementary diagnostic

Networking Lunch

Panel Session hosted by Roche Diagnostics: What are the Places of Complementary and Companion Diagnostics in Immuno-Oncology?

  • Eric Rubin Vice President & Therapeutic Area Head, Oncology Early Development, Merck
  • Miro Venturi Global Head, Diagnostics, Biomarkers, Roche
  • Steven Anderson CSO , Covance
  • Zhen Su Vice President & Head, Global Medical Affairs, Oncology, EMD Serono
  • Bruce Jordan Vice President, International Business Leader, Companion Diagnostics, Roche Diagnostics
  • Steven D. Averbuch, M.D. Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb


  • What does a clear definition of a “complementary diagnostic” look like?
  • How do we maximize the impact of diagnostics in immuno-oncology therapeutic development?
  • Do we need complete standardization between different diagnostic assays targeting the same biomarker?
  • Are we in a position to utilize combination therapies with diagnostics?
  • How are we making decisions on how to develop complementary diagnostics without much guidance?
  • Was the first approval of a complementary diagnostic what the FDA have actually labelled it as?
  • Are the FDA struggling to keep up with the science in the field at large?

Liquid Biopsies in Precision Medicine

Liquid Biopsies: Changing Treatment Paradigms for Patients

  • Stefan Scherer Vice President, Global Head, Correlative Sciences, Novartis


  • Understand the importance and the added value of liquid biopsies in precision medicine and drug development
  • Discussion will be led around how liquid biopsies are shifting us to more real-time treatment decisions for patients in need

Epitope-Indpendent Capture and Harvest of CTCs from Blood

  • Claudia Hille PhD Student, University Medical Center Hamburg - Eppendorf (UKE)


  • Introduction to the operation and performance of the Parsortix CTC capture and harvest system
  • Illustration of the workflows for protein and genomic analysis of CTCs
  • Case studies from collaborations exploring the use of CTCs as companion diagnostics

Afternoon Refreshments

Targeted Therapy, Diagnostic & Technology Regulation & Policy

The Regulatory & Policy Landscape of Precision Medicine’s and Diagnostics: What have we Accomplished?


  • Understand the recent history and important milestones along the timeline for precision therapies, diagnostics and associated technologies
  • Discussion around what is likely to change in the future with regards to drug and device regulation and policy impacting precision medicine
  • An look at key drug-companion diagnostic approvals and what lessons have been taken forward

Panel Session: Achieving Drug, Diagnostic and Tech Regulatory Approval in the U.S. and Other Leading Geographies


  • What can we expect to see from the finalized guidance of LDT’s by the FDA?
  • What can be done to get FDA and the Clinical Lab’s speaking the same regulatory language?
  • What are the key success factors when aligning drug-CDx co-development for regulatory approval and launch?
  • How do you define a biomarker and what is the criteria for a “validated” assay?
  • How do we make the most of breakthrough designations and adaptive licensing?
  • How are we dealing with The EU, China, Japan and beyond with precision medicine regulation?

Close of Day 1

Boston Tea Party Evening Reception, Hosted by Abbott Molecular